Beta Drugs (NSE:BETA) Beneish M-Score: -1.38 (As of Jun. 25, 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
82 GF Score
Price ₹2,096.60
GF Value ₹1,959.98
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Beneish M-Score?

Beta Drugs NSE:BETA -3.13% 82 Beneish M-Score is -1.38 as of Jun. 25, 2026. GuruFocus rates NSE:BETA with a GF Score™ of 82/100 and a GF Value™ of ₹1,959.98 (Fairly Valued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Beta Drugs ranks worse than 89.24% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.38 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Beta Drugs's Beneish M-Score or its related term are showing as below:

NSE:BETA' s Beneish M-Score Range Over the Past 10 Years
Min: -2.69   Med: -2.14   Max: -1.35
Current: -1.38

During the past 13 years, the highest Beneish M-Score of Beta Drugs was -1.35. The lowest was -2.69. And the median was -2.14.


Beta Drugs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Beneish M-Score Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.42 -2.06 -2.14 -2.57 -1.38

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.57 0.00 0.00 -1.38

NSE:BETA vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beta Drugs Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Beneish M-Score falls into.


NSE:BETA
82GF Score
Beta Drugs Ltd NSE:BETA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Beta Drugs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0882+0.528 * 0.9495+0.404 * 2.8737+0.892 * 1.062+0.115 * 0.9313
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.008464-0.327 * 0.9248
=-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹1,191 Mil.
Revenue was ₹3,848 Mil.
Gross Profit was ₹2,136 Mil.
Total Current Assets was ₹3,352 Mil.
Total Assets was ₹4,958 Mil.
Property, Plant and Equipment(Net PPE) was ₹1,154 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹172 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹1,081 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,333 Mil.
Net Income was ₹415 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹373 Mil.
Total Receivables was ₹1,031 Mil.
Revenue was ₹3,624 Mil.
Gross Profit was ₹1,910 Mil.
Total Current Assets was ₹3,311 Mil.
Total Assets was ₹4,362 Mil.
Property, Plant and Equipment(Net PPE) was ₹913 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹125 Mil.
Selling, General, & Admin. Expense(SGA) was ₹139 Mil.
Total Current Liabilities was ₹1,027 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,270 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1191.309 / 3848.258) / (1030.829 / 3623.557)
=0.309571 / 0.28448
=1.0882

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1910.024 / 3623.557) / (2136.459 / 3848.258)
=0.527113 / 0.555176
=0.9495

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3351.607 + 1153.679) / 4957.996) / (1 - (3310.77 + 912.966) / 4362.347)
=0.091309 / 0.031774
=2.8737

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3848.258 / 3623.557
=1.062

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(125.14 / (125.14 + 912.966)) / (171.529 / (171.529 + 1153.679))
=0.120546 / 0.129436
=0.9313

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 3848.258) / (138.698 / 3623.557)
=0 / 0.038277
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1333.247 + 1081.404) / 4957.996) / ((1269.944 + 1027.296) / 4362.347)
=0.487022 / 0.526606
=0.9248

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(414.827 - 0 - 372.861) / 4957.996
=0.008464

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Beta Drugs has a M-score of -1.38 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.38 mean?
Beta Drugs (NSE:BETA) has a Beneish M-Score of -1.38 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beta Drugs and its competitors. According to the industry distribution chart, Beta Drugs ranks #813 out of 911 companies in the Drug Manufacturers industry, placing it in the top 89.2%.
Is Beta Drugs' Beneish M-Score too high?
Beta Drugs' current Beneish M-Score is -1.38. Based on the distribution chart, Beta Drugs ranks #813 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #813 out of 911 companies for Beneish M-Score. This places Beta Drugs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beta Drugs and its competitors. Beta Drugs's current Beneish M-Score is -1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,959.98, compared to a current price of ₹2,096.60 — trading 7% above its estimated fair value. The current Beneish M-Score is -1.38. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Beneish M-Score is -1.38 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,096.60 is trading 7% above its estimated GF Value™ of ₹1,959.98. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • Beneish M-Score: -1.38
  • GF Value™: ₹1,959.98 vs. price of ₹2,096.60 (7% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score

Get the complete analysis for NSE:BETA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,096.60
Price
₹1,959.98
GF Value